skip to main content

Valproate pregnancy prevention — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardCNS TherapeuticsValproate pregnancy preventionGPhC CRA

A 28-year-old woman with epilepsy requests sodium valproate. She says she is sexually active, not using contraception and has not heard of a pregnancy prevention programme. Her seizure control has been stable. What is the most appropriate action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CEscalate to the prescriber before supply unless the required pregnancy-prevention safeguards are confirmed.

Valproate has major teratogenic and neurodevelopmental risks and is subject to strict pregnancy-prevention requirements in people who could become pregnant. If safeguards are not confirmed, the pharmacist should escalate to the prescriber urgently and manage supply in a way that avoids abrupt withdrawal risk. The pharmacist cannot independently switch antiepileptic therapy.

Reference: MHRA Drug Safety Update; BNF